{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:12:20Z","timestamp":1790187140086,"version":"4.1.0"},"reference-count":69,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Cardiovascular Therapy"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/14779072.2021.1955349","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T07:19:46Z","timestamp":1626160786000},"page":"739-751","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Evinacumab for treatment of familial hypercholesterolemia"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3635-7506","authenticated-orcid":false,"given":"Bruce A.","family":"Warden","sequence":"first","affiliation":[{"name":"Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[{"name":"Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, USA"},{"name":"Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000297"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.057"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30041-9"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013225"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318781360"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.10.055"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.04.003"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.03.008"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.179564"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0052-6"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvz015"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.08.007"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.08.051"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90155-6"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6807.893"},{"key":"cit0017","unstructured":"World Health Organization. Familial hypercholesterolaemia (FH): report of a second WHO consultation; 1998. [cited 2021 Apr 29]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/66346\/WHO_HGN_FH_CONS_99.2.pdf;jsessionid=961D48D3A63F73082AAC3EB38D01E871?sequence=1"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.05.044"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.04.011"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.3.331"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301430"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8892"},{"issue":"7","key":"cit0023","first-page":"Cd006401","author":"Vuorio A","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025158"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816454"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu274"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"cit0029","author":"Grundy SM","year":"201","journal-title":"J Am Coll Cardiol"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2020-0490"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.07.018"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.06.011"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01514-2"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913805"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044431"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.12.020"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1707806"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104653"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14450"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2020.45.9.3178109"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.030"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1298"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612790"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M300031-JLR200"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701329"},{"key":"cit0048","unstructured":"U.S.food and drug administration center for drug evaluation and research \u2013 summary review. Evkeeza (evinacumab-dgnb). cited 2021 May 5. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761181Orig1s000SumR.pdf"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.311056"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M054890"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M054882"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.RA119000419"},{"key":"cit0053","unstructured":"Prescribing information. Evkeeza (evinacumab). Tarrytown,Ny: Regeneron Pharmaceuticals, LLC; 2021."},{"key":"cit0054","unstructured":"Prescribing Information. Praluent (alirocumab). Bridgewater, NJ: Sanofi-Aventis U.S., LLC; 2019."},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.039107"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1705994"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004215"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.04.014"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031049"},{"key":"cit0060","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). cited 2020 Apr 30. Available from https:\/\/clinicaltrials.gov\/ct2\/results?cond=evinacumab&term=&cntry=&state=&city=&dist="},{"key":"cit0061","unstructured":"U.S.food and drug administration center for drug evaluation and research \u2013 risk assessment and risk mitigation review(s). Evkeeza (evinacumab-dgnb). [cited 2021 May 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761181Orig1s000RiskR.pdf"},{"key":"cit0062","unstructured":"Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc.) is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. Pharmacy Times. [cited 2021 May 12]. Available from: https:\/\/www.pharmacytimes.com\/view\/fda-approves-first-in-class-therapy-for-ultra-rare-form-of-high-cholesterol"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2018.54.12.2899384"},{"key":"cit0066","doi-asserted-by":"crossref","unstructured":"Rosenson RS. A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia. Abstract 406-19, ACC 2021 Scientific Session, 15-17 May.","DOI":"10.1016\/j.atherosclerosis.2021.06.901"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60312-2"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht571"}],"container-title":["Expert Review of Cardiovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14779072.2021.1955349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T23:19:39Z","timestamp":1672787979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14779072.2021.1955349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/14779072.2021.1955349"],"URL":"https:\/\/doi.org\/10.1080\/14779072.2021.1955349","relation":{},"ISSN":["1477-9072","1744-8344"],"issn-type":[{"value":"1477-9072","type":"print"},{"value":"1744-8344","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierk20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierk20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}